Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review
- 26 March 2018
- journal article
- review article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 16 (9), 1407-1419.e22
- https://doi.org/10.1016/j.cgh.2018.02.051
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- Canadian Association of Gastroenterology
This publication has 138 references indexed in Scilit:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s DiseasePLOS ONE, 2013
- Developing core outcome sets for clinical trials: issues to considerTrials, 2012
- S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled TrialGastroenterology, 2009
- Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding studyBMC Gastroenterology, 2009
- Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialGut, 2007
- Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trialAlimentary Pharmacology & Therapeutics, 2005
- Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's diseaseGut, 1998
- Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month studyAlimentary Pharmacology & Therapeutics, 1998
- A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's DiseaseNew England Journal of Medicine, 1989